{
  "disease_name": "Lysinuric protein intolerance",
  "orpha_code": "470",
  "drugs": [
    {
      "name": "Sodium benzoate",
      "substance_url": "/en/drug/substance/83694?name=470&mode=orpha&region=&status=all",
      "substance_id": "83694",
      "regulatory_url": "/en/drug/regulatory/480490?name=470&mode=orpha&region=",
      "regulatory_id": "480490",
      "orpha_substance_code": "ORPHA:470",
      "details": [
        "Sodium benzoate(Medicinal product                        - 29/08/2016)Disease(s) concernedORPHA:470 Lysinuric protein intolerance",
        "Sodium benzoate(Medicinal product                        - 29/08/2016)",
        "(Medicinal product                        - 29/08/2016)",
        "Disease(s) concernedORPHA:470 Lysinuric protein intolerance",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/83694?name=470&mode=orpha&region=&status=all",
          "text": "Sodium benzoate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/470",
          "text": "ORPHA:470 Lysinuric protein intolerance",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/480490?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "DEQSIGA",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/700589?name=470&mode=orpha&region=",
      "regulatory_id": "700589",
      "orpha_substance_code": "ORPHA:101997",
      "details": [
        "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
        "DEQSIGA(Tradename                        - 02/05/2025)",
        "(Tradename                        - 02/05/2025)",
        "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/700586?name=470&mode=orpha&region=&status=all",
          "text": "DEQSIGA",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/3002",
          "text": "ORPHA:3002 Immune thrombocytopenia",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/2331",
          "text": "ORPHA:2331 Kawasaki disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/2103",
          "text": "ORPHA:2103 Guillain-Barré syndrome",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/2932",
          "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/641",
          "text": "ORPHA:641 Multifocal motor neuropathy",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/101997",
          "text": "ORPHA:101997 Primary immunodeficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/700589?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US",
        "EU"
      ]
    },
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=470&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=470&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=470&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=470&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=470&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=470&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=470&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=470&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=470&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=470&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=470&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=470&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=470&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "tadekinig alfa",
      "substance_url": "/en/drug/substance/448814?name=470&mode=orpha&region=&status=all",
      "substance_id": "448814",
      "regulatory_url": "/en/drug/regulatory/484711?name=470&mode=orpha&region=",
      "regulatory_id": "484711",
      "orpha_substance_code": "ORPHA:158032",
      "details": [
        "tadekinig alfa(Medicinal product                        - 14/10/2016)Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
        "tadekinig alfa(Medicinal product                        - 14/10/2016)",
        "(Medicinal product                        - 14/10/2016)",
        "Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/448814?name=470&mode=orpha&region=&status=all",
          "text": "tadekinig alfa",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/158032",
          "text": "ORPHA:158032 Hemophagocytic syndrome",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/484711?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "emapalumab",
      "substance_url": "/en/drug/substance/222653?name=470&mode=orpha&region=&status=all",
      "substance_id": "222653",
      "regulatory_url": "/en/drug/regulatory/240327?name=470&mode=orpha&region=",
      "regulatory_id": "240327",
      "orpha_substance_code": "ORPHA:158032",
      "details": [
        "emapalumab(Medicinal product                        - 09/06/2010)Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
        "emapalumab(Medicinal product                        - 09/06/2010)",
        "(Medicinal product                        - 09/06/2010)",
        "Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/222653?name=470&mode=orpha&region=&status=all",
          "text": "emapalumab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/158032",
          "text": "ORPHA:158032 Hemophagocytic syndrome",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/240327?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "GAMIFANT",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/539493?name=470&mode=orpha&region=",
      "regulatory_id": "539493",
      "orpha_substance_code": "ORPHA:158038",
      "details": [
        "GAMIFANT(Tradename                        - 20/11/2018)Disease(s) concernedORPHA:158038 Primary hemophagocytic lymphohistiocytosis",
        "GAMIFANT(Tradename                        - 20/11/2018)",
        "(Tradename                        - 20/11/2018)",
        "Disease(s) concernedORPHA:158038 Primary hemophagocytic lymphohistiocytosis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/539491?name=470&mode=orpha&region=&status=all",
          "text": "GAMIFANT",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/158038",
          "text": "ORPHA:158038 Primary hemophagocytic lymphohistiocytosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/539493?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=470&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=470&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=470&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Fully human IgG1 monoclonal antibody directed against human signal regulatory protein (SIRP)alpha, SIRPbeta1, and SIRPgamma",
      "substance_url": "/en/drug/substance/689517?name=470&mode=orpha&region=&status=all",
      "substance_id": "689517",
      "regulatory_url": "/en/drug/regulatory/689727?name=470&mode=orpha&region=",
      "regulatory_id": "689727",
      "orpha_substance_code": "ORPHA:158032",
      "details": [
        "Fully human IgG1 monoclonal antibody directed against human signal regulatory protein (SIRP)alpha, SIRPbeta1, and SIRPgamma(Medicinal product                        - 02/10/2024)Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
        "Fully human IgG1 monoclonal antibody directed against human signal regulatory protein (SIRP)alpha, SIRPbeta1, and SIRPgamma(Medicinal product                        - 02/10/2024)",
        "(Medicinal product                        - 02/10/2024)",
        "Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689517?name=470&mode=orpha&region=&status=all",
          "text": "Fully human IgG1 monoclonal antibody directed against human signal regulatory protein (SIRP)alpha, SIRPbeta1, and SIRPgamma",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/158032",
          "text": "ORPHA:158032 Hemophagocytic syndrome",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689727?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=470&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=470&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=470&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=470&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=470&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=470&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "tadekinig alfa",
      "substance_url": "/en/drug/substance/448814?name=470&mode=orpha&region=&status=all",
      "substance_id": "448814",
      "regulatory_url": "/en/drug/regulatory/484722?name=470&mode=orpha&region=",
      "regulatory_id": "484722",
      "orpha_substance_code": "ORPHA:158032",
      "details": [
        "tadekinig alfa(Medicinal product                        - 12/01/2017)Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
        "tadekinig alfa(Medicinal product                        - 12/01/2017)",
        "(Medicinal product                        - 12/01/2017)",
        "Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/448814?name=470&mode=orpha&region=&status=all",
          "text": "tadekinig alfa",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/158032",
          "text": "ORPHA:158032 Hemophagocytic syndrome",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/484722?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=470&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=470&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=470&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=470&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=470&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=470&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=470&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T06:00:24.603038",
  "run_number": 1,
  "total_drugs_found": 17,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Lysinuric+protein+intolerance&orphaCode=470&name=470&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Lysinuric protein intolerance",
    "orphaCode": "470",
    "name": "470",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}